| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.03 | 50.0% | 0.0% |
| Total Income | 0.03 | 50.0% | 0.0% |
| Expenditure | 3.54 | 57.3% | 32.6% |
| PBT | — | ||
| Net Profit | -3.79 | 25.5% | 35.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.43 | 37.7% | 88.3% |
AIM ImmunoTech Reports Q2 2026 Financial Results and Operational Highlights
10 Aug 2026 · 10 Aug, 6:17 pm
Summary
AIM ImmunoTech reported its financial results for the second quarter ended June 30, 2026, alongside significant operational updates. The company highlighted the completion of patient enrollment and Ampligen dosing in its Phase 2 DURIPANC study for metastatic pancreatic cancer, a key step towards planned Phase 3 development. While R&D expenses decreased to $589,000 in Q2 2026 from $1.2 million in Q2 2025, the net loss widened to $(3.8 million) from $(2.8 million) year-over-year. Management emphasized a disciplined strategy focused on advancing Ampligen in pancreatic cancer and strengthening the company's financial position.
Key Highlights
- 1
AIM ImmunoTech reported financial results for the second quarter ended June 30, 2026, highlighting operational execution in its pancreatic cancer program.
- 2
The company completed patient enrollment and Ampligen dosing in the Phase 2 DURIPANC study for metastatic pancreatic cancer.
- 3
AIM strengthened its balance sheet through multiple financing transactions, providing additional resources for clinical execution.
- 4
The company successfully regained full compliance with NYSE American's continued listing standards.
- 5
Research and development expenses for Q2 2026 were approximately $589,000, a decrease from $1.2 million in Q2 2025.
- 6
Net loss for Q2 2026 was approximately $(3.8 million), or $(0.43) per share, compared to $(2.8 million), or $(3.68) per share, in Q2 2025.
Management Comments
Thomas K. Equels
AIM continues to execute a clear and disciplined strategy centered on advancing Ampligen in pancreatic cancer. Over the past year, we have strengthened our financial position while completing enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as we move toward an anticipated Phase 3 study in metastatic pancreatic cancer. We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027. AIM expects that this data will amplify median Overall Survival findings from Ampligen’s Dutch-government approved Named Patient Program in late-stage pancreatic cancer, where Ampligen achieved a median Overall Survival of 34.8 months compared to 12.5 months for historical controls – with favorable safety profile and high quality of life – in a large, easily identifiable and key patient immune biomarker subset. This median improvement of 22.3 months will be a critical component of the foundation for our pivotal Phase 3 clinical trial design in metastatic pancreatic cancer.
Informational and educational content only. Not investment advice.